Journal of Diabetes & Clinical Practice

Hiroshi, J Diabetes Clin Prac 2024, 7:5

Mini Review Open Access

Emerging Biomarkers for Early Detection of Diabetic Kidney Disease

Hiroshi Tanaka*

Department of Endocrinology and Metabolism, University of Tokyo, Japan

Abstract

Diabetic kidney disease (DKD) is a significant complication of diabetes and a leading cause of end-stage renal disease worldwide. Early detection and intervention are crucial for preventing progression to advanced stages of kidney disease. Traditional biomarkers, such as serum creatinine and urinary albumin, often fail to detect early changes in renal function. This article reviews emerging biomarkers for the early detection of DKD, including novel urinary, serum, and genetic markers, discussing their potential clinical applications and implications for management.

Keywords: Diabetic Kidney Disease; Biomarkers; Early Detection, Nephrology; Diabetes Management; KIM-1; NGAL; Cystatin C; Genetic Predisposition; Micrornas

Introduction

Diabetes mellitus, particularly Type 2 diabetes, is one of the most prevalent chronic diseases globally. Among its numerous complications, diabetic kidney disease (DKD) stands out as a major cause of morbidity and mortality. The pathophysiology of DKD involves complex interactions between metabolic derangements, hemodynamic changes, and inflammation. Early detection of DKD is critical, as timely intervention can prevent or delay the progression to end-stage renal disease (ESRD). Traditional markers like serum creatinine and urinary albumin have limitations in sensitivity and specificity, prompting the search for emerging biomarkers that can facilitate earlier diagnosis and improved patient outcomes.

Diabetic kidney disease is characterized by structural and functional changes in the kidneys due to prolonged exposure to high blood glucose levels [1]. These changes often manifest as glomerulosclerosis, tubulointerstitial fibrosis, and alterations in kidney hemodynamics. Clinically, DKD is classified into stages based on the degree of albuminuria and the estimated glomerular filtration rate (eGFR). However, the onset of kidney injury may occur long before these changes are detectable through standard clinical measures, underscoring the need for more sensitive diagnostic tools.

The Need for Early Detection

The progression of DKD typically follows a clinical course characterized by a gradual decline in glomerular filtration rate (GFR) and increasing albuminuria [2]. However, significant renal damage can occur before these changes are detectable by standard clinical measures. As such, there is a pressing need for more sensitive biomarkers that can identify early kidney injury, allowing for timely therapeutic interventions. Recent research has identified several promising biomarkers that may enhance our ability to detect DKD at earlier stages.

Emerging Biomarkers

Urinary Biomarkers

Kidney Injury Molecule-1 (KIM-1): KIM-1 is a transmembrane protein that is upregulated in response to renal injury. Studies have shown that urinary KIM-1 levels are elevated in patients with DKD, making it a potential early marker of kidney damage [3]. KIM-1 has been associated with tubular injury and may provide insights into the progression of DKD.

Neutrophil Gelatinase-Associated Lipocalin (NGAL): NGAL is a lipocalin protein released by neutrophils and renal tubular cells during injury. Increased levels of urinary NGAL have been linked to early-stage DKD and can serve as a sensitive marker for acute kidney injury, indicating renal stress before significant changes in creatinine or albumin levels.

Osteopontin (OPN): OPN is involved in inflammation and fibrosis, processes relevant to DKD. Elevated urinary OPN levels have been associated with early kidney damage and may serve as a predictive biomarker for DKD progression.

Serum Biomarkers

Cystatin C: Cystatin C is a cysteine protease inhibitor that reflects glomerular filtration rate more accurately than creatinine, especially in the early stages of kidney disease [4]. Elevated serum levels of cystatin C have been associated with the onset of DKD and may offer advantages over traditional creatinine-based assessments.

Serum Dipeptidyl Peptidase-4 (DPP-4): DPP-4 is an enzyme involved in glucose metabolism and has been implicated in renal function. Increased serum levels of DPP-4 have been associated with DKD, suggesting its potential role as a biomarker for kidney injury in diabetic patients.

Genetic Biomarkers

Single Nucleotide Polymorphisms (SNPs): Genetic predisposition plays a significant role in the development of DKD. Several SNPs, such as those in the APOL1 and KCNJ1 genes, have been associated with an increased risk of kidney disease in diabetic individuals [5]. Identifying these genetic markers could help stratify patients based on their risk for developing DKD, enabling personalized management strategies.

MicroRNAs (miRNAs): Emerging evidence suggests that specific miRNAs may serve as biomarkers for kidney injury. Dysregulated

***Corresponding author:** Hiroshi Tanaka, Department of Endocrinology and Metabolism, University of Tokyo, Japan E-mail: tanaka_87hiroshi@yahoo.com

Received: 02-Sep-2024, Manuscript No: jdce-24-149226, **Editor Assigned:** 05-Sep-2024, pre QC No: jdce-24-149226 (PQ), **Reviewed:** 20-Sep-2024, QC No: jdce-24-149226, **Revised:** 24-Sep-2024, Manuscript No: jdce-24-149226 (R), **Published:** 30-Sep-2024, DOI: 10.4172/jdce.1000269

Citation: Hiroshi T (2024) Emerging Biomarkers for Early Detection of Diabetic Kidney Disease. J Diabetes Clin Prac 7: 269.

miRNAs, such as miR-29 and miR-192, have been linked to renal fibrosis and inflammation in DKD. These small non-coding RNAs may provide novel insights into the molecular pathways involved in DKD and serve as potential diagnostic tools.

Clinical Implications

The identification of emerging biomarkers for DKD has several clinical implications:

Enhanced Screening: Incorporating novel biomarkers into routine clinical practice could improve the early detection of DKD, allowing for timely interventions that may slow disease progression.

Personalized Treatment Approaches: Understanding individual risk factors, including genetic predisposition and biomarker profiles, can guide personalized treatment strategies, optimizing therapeutic outcomes for patients with diabetes.

Monitoring Disease Progression: Emerging biomarkers may offer additional information about the progression of DKD, helping clinicians assess the effectiveness of interventions and adjust treatment plans accordingly.

Research and Drug Development: Biomarkers can facilitate the development of new therapeutic agents aimed at specific pathways involved in DKD [6]. Understanding the underlying mechanisms of kidney injury may lead to targeted therapies that can prevent or reverse damage.

Challenges and Future Directions

While emerging biomarkers hold promise, several challenges remain:

Validation: Many of these biomarkers require further validation in large, diverse populations to confirm their utility in clinical practice. Rigorous studies are needed to establish sensitivity, specificity, and predictive values.

Standardization: Standardized methods for measuring emerging biomarkers must be established to ensure consistency and comparability across studies and clinical settings.

Integration into Clinical Practice: Integrating new biomarkers into routine clinical practice involves training healthcare providers and ensuring that testing methods are accessible and cost-effective [7].

Ethical Considerations: The use of genetic and molecular biomarkers raises ethical questions regarding patient privacy, informed consent, and the potential for discrimination based on genetic predisposition [8-10].

Conclusion

Diabetic kidney disease represents a significant challenge in managing diabetes-related complications. Early detection is crucial for preventing progression to advanced renal disease, and emerging biomarkers offer a promising avenue for improving diagnostic accuracy. Urinary and serum biomarkers, along with genetic indicators, hold potential for enhancing the understanding of DKD and facilitating timely interventions. As research continues to evolve, the integration of these biomarkers into clinical practice could transform the management of DKD, ultimately improving outcomes for patients with diabetes.

References

1. Kathryn BS (2003) Poor prognosis of young adults with type 1 diabetes. Diabetes Care 26: 1052-1057.
2. Das-Munshi J, Stewart R, Ismail K, Bebbington PE, Jenkins R, et al. (2007) Diabetes, common mental disorders, and disability: findings from the UK National Psychiatric Morbidity Survey. Psychosom Med 69: 543-550.
3. Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, et al. (2008) Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 3: 2398-2403
4. Centorrino F, Hernan MA, Drago-Ferrante G, Rendall M (2009) The economic burden of comorbid psychiatric and endocrine disorders: a systematic review and meta-analysis. Psychiatr Serv 60: 693-702.
5. Balhara YP (2011) Diabetes and psychiatric disorders. Indian J Endocrinology and Metabolism 15: 274-283.
6. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH (2004) Diabetes, depression and quality of life: a population study. Diabetes Care 27: 1066-1070.
7. Schram MT, Baan CA, Pouwer F (2009) Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium. Curr Diabetes Rev 5: 112-119.
8. Hutter N, Schnurr A, Baumeister H (2010) Healthcare costs in patients with diabetes mellitus and comorbid mental disorders-a systematic review. Diabetologia 53: 2470-2479.
9. Wu Y, Ding Y, Tanaka Y, Zhang W (2014) Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci 11: 1185.
10. Gilani SR, Feizabad AK (2019) The effects of aerobic exercise training on mental health and self-esteem of type 2 diabetes mellitus patients. Health psychology research 7: 6576.